Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,000 shares, as reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value ...

In a recent SEC filing, it was revealed that David A Ricks, President at Eli Lilly LLY, made a noteworthy insider purchase on August 12,. What Happened: Ricks demonstrated confidence in Eli Lilly by ...

Texas Attorney General Ken Paxton said the state is suing Eli Lilly for allegedly bribing clinicians to prescribe its GLP-1 ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...